ARENSIA Spotlight Session, May 24th, San Francisco, CA

We are pleased to announce ARENSIA Spotlight Session "Innovative Strategies to Achieve First Efficacy Data / Proof-of-Concept in Record Time", which will take place on 24th May 2017 in San Francisco, CA.

In today's fast-changing world, to stay competitive means to be innovative and open to embrace new approaches. Industry is facing time-pressing competition when fast movement through exploratory clinical phase is posing great challenges. Early go/no-go...

2016 In Review: Message from CEO and Co-Founder Claudia Hesselmann

At ARENSIA, we are looking back on a very good business year, in which we were able to outdo ourselves with regard to outstanding patient enrolment rates in complex Phase 1, 2a, POC studies at our Phase 1 units in Eastern Europe. Studies involved sophisticated logistics, biomarker assessments (e.g. biopsy collection and imaging), intensive PK, hospitalization, in various indications and in populations.

We continue observing high interest from Sponsors in "integrated" protocol designs: First-in-Man in healthy volunteers performed at Phase 1 CROs in Western Europe or US +...

NEW PHASE I UNIT FOR PEDIATRICS STUDIES, BUCHAREST, ROMANIA

As of August 2015, ARENSIA expands its operations with a new clinical research unit in Bucharest, Romania.

This unit is fully dedicated to exploratory clinical trials Phase 1 and 2 in PEDIATRIC patients (age 0-18) with chronic and acute conditions, such as:

-       Respiratory

-       Immunology (incl. rheumatology & allergies)

-       Eye condition (retinopathy of prematurity)

-      ...

ARENSIA-Record fast recruitment rates

Update on how ARENSIA kept its promise of fast recruitment, quality and innovation, at the same time getting better for our Sponsors in 2015.

Summary:

- Record fast recruitment for clients in 50+ PATIENT studies Phase 1, 2a, PROOF OF CONCEPT in 2014

- New ARENSIA Phase 1 unit in Tbilisi, Georgia started-up in 2014.

- Fast and cost efficient: umbrella protocols First-in-Man healthy in Western Europe + First-in-Patient at ARENSIA Eastern Europe.

In 2014, we confirmed again our reputation of record fast recruitment rates in more than 50 Phase 1, 2a, POC studies at our Phase 1 units...

ARENSIA offers now stand-alone QA services!

As a separate service ARENSIA Quality Assurance department offers customized auditing solutions with focus on Eastern European countries to ensure that clinical trials are consistently performed at highest GCP level.

ARENSIA has a highly qualified Quality Assurance department, which provides on-demand auditing support for projects running inside ARENSIA facilities or entirely independently to the pharmaceutical and CRO companies.

ARENSIA┬┤s team of auditors has long-year experience in Quality Management with profound knowledge of...

Contact

ARENSIA Exploratory Medicine GmbH

Merowingerplatz 1
40225 Duesseldorf, Germany

Email: undefinedinfo(at)arensia-em.com

Office phone: +49 (211) 15 77 89 0
Office fax:      +49 (211) 15 77 89 10

undefinedContact form